O. Suprun, A. Bagriy, E. Mykhailichenko, M. Krivushcheva
{"title":"胰高血糖素样肽-1受体激动剂在2型糖尿病患者中的应用","authors":"O. Suprun, A. Bagriy, E. Mykhailichenko, M. Krivushcheva","doi":"10.32756/0869-5490-2022-2-63-68","DOIUrl":null,"url":null,"abstract":"An article reviews the use of glucagon-like peptide-1 (GLP-1) receptor agonists for treatment of patients with type 2 diabetes mellitus associated with high cardiovascular risk, chronic heart failure with low left ventricular ejection fraction and diabetic nephropathy. The authors discuss the mechanisms of action of GLP-1 receptor agonists, their main advantages (significant hypoglycemic effect, organoprotection and improved cardiovascular and renal outcomes) and dosedependent side effects.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"48 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus\",\"authors\":\"O. Suprun, A. Bagriy, E. Mykhailichenko, M. Krivushcheva\",\"doi\":\"10.32756/0869-5490-2022-2-63-68\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"An article reviews the use of glucagon-like peptide-1 (GLP-1) receptor agonists for treatment of patients with type 2 diabetes mellitus associated with high cardiovascular risk, chronic heart failure with low left ventricular ejection fraction and diabetic nephropathy. The authors discuss the mechanisms of action of GLP-1 receptor agonists, their main advantages (significant hypoglycemic effect, organoprotection and improved cardiovascular and renal outcomes) and dosedependent side effects.\",\"PeriodicalId\":10353,\"journal\":{\"name\":\"Clinical pharmacology and therapy\",\"volume\":\"48 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-06-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical pharmacology and therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.32756/0869-5490-2022-2-63-68\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical pharmacology and therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32756/0869-5490-2022-2-63-68","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus
An article reviews the use of glucagon-like peptide-1 (GLP-1) receptor agonists for treatment of patients with type 2 diabetes mellitus associated with high cardiovascular risk, chronic heart failure with low left ventricular ejection fraction and diabetic nephropathy. The authors discuss the mechanisms of action of GLP-1 receptor agonists, their main advantages (significant hypoglycemic effect, organoprotection and improved cardiovascular and renal outcomes) and dosedependent side effects.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
